An in vivo genome‐wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer

Paclitaxel is a common breast cancer drug; however, some tumors are resistant. The identification of biomarkers for paclitaxel resistance or sensitivity would enable the development of strategies to improve treatment efficacy. A genome‐wide in vivo shRNA screen was performed on paclitaxel‐treated mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sultan, Mohammad, Nearing, Jacob T., Brown, Justin M., Huynh, Thomas T., Cruickshank, Brianne M., Lamoureaux, Emily, Vidovic, Dejan, Dahn, Margaret L., Fernando, Wasundara, Coyle, Krysta M., Giacomantonio, Carman A., Langille, Morgan G.I., Marcato, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333778/
https://www.ncbi.nlm.nih.gov/pubmed/33932086
http://dx.doi.org/10.1002/1878-0261.12964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333778/
https://www.ncbi.nlm.nih.gov/pubmed/33932086
http://dx.doi.org/10.1002/1878-0261.12964

Ejemplares similares